CRO & Clinical Services

Micropep develops AI-powered discovery and development platforms for bioactive micropeptides used in sustainable crop protection and stimulation. The company combines generative AI, predictive modeling, and experimental data to accelerate the identification and optimization of micropeptide-based biocontrol products targeting fungal diseases, bioherbicide applications, and crop health enhancement. Micropep's lead product MPD-01, an antimicrobial peptide targeting Asian soybean rust, mildews, and late blight, is currently undergoing field trials across Europe, the US, and Latin America in preparation for regulatory submission.

BMG LABTECH is a leading developer and manufacturer of microplate reader instrumentation for high-throughput screening and life science applications in pharmaceutical and academic research. The company offers both dedicated luminescence plate readers and multi-mode systems with advanced detection capabilities including absorbance, luminescence, and specialized assay technologies. Their microplate readers are designed for easy integration into automated systems and feature capabilities such as well-scanning, incubation, shaking, and reagent injection for enhanced workflow efficiency.

Porvair Sciences is a UK-based manufacturer specializing in microplates, microplate instrumentation, and porous plastic materials for biotechnology and life science industries. They offer a diverse portfolio including assay kits, automated laboratory equipment, and precision-assembled microplates to enhance sample preparation, analysis, and workflow efficiency. As a subsidiary of Porvair plc, they provide high-quality products supported by a global network of distributors.

Leica Microsystems develops high-tech precision microscopes and imaging systems for life science research, biotechnology, medicine, and pharmaceutical analysis of microstructures and nanostructures. Their portfolio includes digital microscopes for biological sciences, materials analysis, and industrial quality assurance, enhanced by machine learning and automation. As part of Danaher Corporation, they operate globally with headquarters in Wetzlar, Germany, and presence in over 100 countries.

Molecular Devices provides high-performance bioanalytical instruments for life science research and pharmaceutical development, including multi-mode microplate readers, cellular imaging systems, and high-content screening solutions. Their technologies support high-throughput screening, genomic and cellular analysis, colony selection, and microplate detection for applications like drug discovery, GPCR/ion channel studies, and stem cell research. Products such as the SpectraMax iD5e and iD3s readers offer tunable detection, dual injectors, and environmental controls for assays including ELISA, cell viability, and protein quantitation.

Nanoworx B.V. is a Netherlands-based Contract Research Organization specializing in nanomedicine development for pharmaceutical and biotech clients. They offer nanoparticle design and prototyping, high-throughput library construction and screening, scaled production, and in vitro assay testing. These customizable services support all stages of nanomedicine advancement, from early design to optimization.

CETONI GmbH specializes in high-precision fluidic systems, including modular Nemesys syringe pumps and flow systems for sub-nanoliter dosing in life sciences and pharma R&D. They offer CETONI Elements, a modular software for automating laboratory processes and integrating devices like sensors via CAN bus and I/O modules. These solutions support microfluidic applications, chemical process development, and industrial precision dosing.

CETONI offers Nemesys modular syringe pumps and Cobomation microfluidic solutions for high-precision fluid handling in life sciences and pharma R&D. These systems provide pulsation-free dosing from 2 nl/min to 1500 ml/min, pressures up to 1000 bar, and software control for continuous flow applications. They support demanding tasks like high-throughput and ultra-high pressure dosing with force and pressure measurement.

Objective Biotechnology develops fully automated microinjection systems for large-scale genetic manipulation of cells and organisms, including the Autoinjector for precise embryo injections in gene editing and transgenesis. The technology uses machine learning and computer vision to enhance speed, consistency, and accessibility in genetic research across insect and vertebrate models. Based in Minneapolis, MN, the company supports researchers in streamlining complex protocols previously requiring extensive manual training.

CN Bio is a world-leading provider of organ-on-chip microphysiological systems (MPS) that accelerate drug discovery and development. Their PhysioMimix platform enables pharmaceutical companies to recreate human organs and tissues in vitro for drug efficacy, safety, and ADME profiling before clinical trials. By offering both single and multi-organ capabilities with reliable microfluidics and computational modeling tools, CN Bio reduces development time and costs while improving predictive accuracy compared to traditional cell culture and animal models.

Peapod Bio is a Chicago-based contract research organization (CRO) specializing in small molecule drug discovery services. They provide assay development, high-throughput screening (HTS), and hit-to-lead solutions using innovative label-free mass spectrometry, fluorescence, HTRF, AlphaLISA, and optical technologies. Their tailored biochemical and binding assays support pharmaceutical R&D from early-stage screening to lead optimization.

PGxAI provides an AI-powered pharmacogenomics platform that delivers personalized drug selection, dosage recommendations, and interaction predictions using machine learning and real-world data. It supports biopharmaceutical sponsors, CROs, and healthcare providers by optimizing clinical trial design, reducing adverse drug reactions, and generating pharmacogenomic reports covering over 730 drugs and 40 genes. The platform integrates generative models, LLMs, and partnerships like Sequencing.com and Novo Genomics to enhance precision medicine.

PGxAI offers AI-driven pharmacogenomics solutions powered by generative AI and real-world evidence for life sciences and pharma. It provides predictive analytics to optimize clinical trial design, identify patient cohorts, and predict drug-gene interactions for CROs and biopharma sponsors. The platform delivers real-time genomic recommendations, automates PGx guideline creation, and personalizes drug treatments like GLP-1 therapies based on genetic profiles.

Dassault Systèmes provides digital solutions for pharmaceutical and biotech companies, covering concept to manufacturing, clinical trials, and supply chain optimization. Their 3DEXPERIENCE platform enables virtualization, simulation, and data-driven decisions to ensure high-quality production as designed and registered. Solutions include agile production scheduling to improve delivery times and resource optimization, alongside molecular modeling for drug development.

Phesi provides AI-driven patient-centric data analytics through its Trial Accelerator platform, simulating clinical trials with data from over 132 million patients across 4,000 diseases and 485,000 trials. The platform supports protocol design, site selection, patient enrollment forecasting, and digital twins for external control arms to optimize trial efficiency and diversity. Trusted by leading pharmaceutical companies, it accelerates development for rare and common indications in nearly 200 countries.

Spectral Instruments Imaging manufactures advanced preclinical in-vivo optical imaging systems for bioluminescence, fluorescence, and X-ray imaging used in disease research and drug development. The company provides co-registered multi-modality imaging platforms with high-sensitivity detection capabilities, field-upgradable options, and integrated software solutions for small animal models and cell-based assays. Founded in 2009 and acquired by Bruker Corporation in 2024, SII serves pharmaceutical and biomedical research organizations requiring quantitative 3D optical imaging for preclinical studies.

DEBRA organizations, including DEBRA of America and DEBRA Research, support pharmaceutical R&D for Epidermolysis Bullosa (EB) therapies through research funding, infrastructure projects like patient registries and biobanks, and partnerships with industry. They facilitate clinical trial networks, preclinical models, and collaborations with pharma companies such as LEO Pharma to advance EB treatments. These non-profits connect developers with patient communities and global experts to accelerate therapy development.

ProPharma Group is a leading global provider of regulatory, clinical, compliance, pharmacovigilance, and medical information services for pharmaceutical, biotechnology, and medical device companies. They support products across the full lifecycle from early development through clinical trials, regulatory approval, and commercialization. Expertise spans therapeutic areas including oncology, cell and gene therapy, obesity, and infectious diseases, with technology-enabled solutions like the Prodigy platform.

Provectus Algae develops scalable biomanufacturing platforms using photosynthetic microalgae and Precision Photosynthesis technology to produce high-value compounds for pharmaceuticals, nutraceuticals, and therapeutics. Their closed-system bioreactors enable controlled production of target substances like peptides, proteins, and bioactive ingredients for drug development and synthetic biology applications. The company supports R&D in sustainable bioproducts across food, cosmetics, agriculture, and pharma sectors.

Q2 Solutions is a leading global clinical trial laboratory services organization offering end-to-end lab services, including bioanalytical testing, ADME, biospecimen management, and biobanking. It provides specialized capabilities in genomics, bioinformatics, DNA/RNA sequencing, companion diagnostics, safety testing, flow cytometry, and anatomic pathology. As an IQVIA company, it delivers tailored solutions with rapid turnaround for pharmaceutical and life sciences clinical trials.

MeMed develops host-immune response diagnostics, including the FDA-cleared MeMed BV test that distinguishes bacterial from viral infections in 15 minutes using serum or whole blood on the compact MeMed Key platform. The test measures immune proteins like TRAIL, IP-10, and CRP with machine learning for actionable scores, aiding antibiotic stewardship and reducing antimicrobial resistance. Additional products like MeMed BV Flex (FDA Breakthrough Designation for capillary blood) and MeMed Severity (for predicting severe outcomes) expand point-of-care capabilities in hospitals and decentralized settings.

SMi Systems develops super-resolution single molecule imaging platforms for biomedical research and diagnostics. Their integrated system includes instruments, consumables in 96-well formats, and software for automated detection, quantification, and analysis of multiple molecule types. The patented technology enables high-throughput imaging of hundreds of thousands of molecules simultaneously, reducing project timelines and costs.

Sannova Analytical is a boutique contract research organization providing comprehensive bioanalytical CRO services for pharmaceutical development, including PK research, DMPK, immunogenicity assays, and high-resolution mass spectrometry for small molecules, proteins, and oligonucleotides. They offer analytical CMC and QC services such as stability testing, ion chromatography, particle size determination, and extractables/leachables testing. Sannova supports clients with direct services, collaboration with preferred clinical providers, or full project management from protocol design to final reporting.

Inventia Life Science offers scalable 3D cell culture solutions via the RASTRUM bioprinting platform, enabling reproducible, human-relevant in vitro models for drug discovery and preclinical studies. They provide Validated Solutions with predefined model blueprints, Discovery Mode for flexibility, and Discovery Services for custom indication-specific models in oncology, fibrosis, neurology, and immunology. These tools support high-throughput production, phenotypic screening, and model transfer to client sites, improving predictive power and translational relevance.